Tailoring Clinical Trials Ensures Launch Success, Maximizes Budgets

Enhance Efficiency and Patient Engagement in Clinical Trials with Expert Support.

Navigating NASH Treatment – Future Therapies

Potential Therapies for chronic liver diseases

Putting a Spotlight on Supporting Rare Disease Patients and Families

2024 Rare Disease Day: Thursday, February 29, 2024

Putting a Spotlight on Supporting Rare Disease Patients and Families

2024 Rare Disease Day: Thursday, February 29, 2024

Unlocking Potential: Exploring Cell and Gene Therapies in Disease Treatment

Cell and gene therapies potential treatment options for various diseases.

Navigating the Challenges of Rare Disease Therapies

Understanding the Valuable Role of a Specialty Pharmacy Solutions Provider.

Advancements in Treatment Options for Ulcerative Colitis and Crohn’s Disease

Additional therapy options for these autoimmune conditions.

Looking Ahead to 2024: Robust Outlook for Specialty Drugs, Cell and Gene Therapies

Significant industry trends worth watching in the new year.

Navigating Alzheimer's: Insights into Innovative Treatments and Ongoing Challenges

Reviewing approaches to treatment and current management options.

HUB & Patient Support Solutions Complement Pre-Commercialisation Services

Working with manufacturers to implement end-to-end solutions that support all initiatives throughout the product lifecycle.

Complex Landscape of Plaque Psoriasis and Pioneering Treatments

Looking at Psoriasis, the chronic disease which affects the immune system.

From Development to Access: Overcoming the Challenges of Clinical Trials for Specialty Drugs, Cell & Gene Therapies

Navigating the challenges of clinical trials for patients with rare genetic diseases.

Unraveling MND and ALS for Hope Amidst Progression

Research advances for enhanced therapies to improve the lives of patients.

Unveiling Progress: NeuroSolv Therapeutics’ Path to Advancing Spinal Cord Injury Treatment

Promising therapy for spinal cord injury treatments through groundbreaking science.

First Gene Therapy for Rare Skin Disorder, Offering New Hope for Wound Healing in Dystrophic Epidermolysis Bullosa (DEB)

Vyjuvek™ (beremagene geperpavec), a topical gene therapy for the relief of a rare genetic skin disorder.

Complete End-to-End Solutions Optimise Rare Disease Clinical Trials and Product Commercialisation

Pharmaceutical manufacturers rely upon AscellaHealth as a single resource for managing all phases of rare disease clinical trials.

The Changing Biosimilar Landscape

Biologic medications bring hope to patients suffering from a variety of specialty conditions.

Spinal Cord Injuries: The Impacts, Current and Future Treatments

Looking at treatments with the potential to enhance outcomes for those suffering from spinal cord injuries.

A Look at von Willebrand Disease

An inherited blood clotting disorder caused by either a deficiency or a dysfunction of the von Willebrand factor (vWf) protein.

Pharmaceutical Companies Turn to AscellaHealth for Consultative Business Model, Including Robust Pre-Commercialisation and Market Access Services

Specialty drug manufacturers are seeking innovative approaches to effectively launch new products.

First Gene Therapy for Haemophilia B, HEMGENIX® Approved by the European Commission

Exciting news about conditional marketing authorisation for gene therapy for the treatment of Haemophilia B.

Optimising Market Access for Rare Disease Products – NEW Market Access Guide now available

A step-by-step guide for EU/UK stakeholders to bring products to market.

Potential New Therapies on the Horizon for Duchenne Muscular Dystrophy

New hope for people living with the rare genetic disorder DMD in the UK.

End-to-End Solutions Optimise Rare Disease Clinical Trials and Product Commercialisation

AscellaHealth a trusted Specialty Pharmacy solutions partner for rare disease clinical trials and implementing go-to-market strategies.

Specialty pharmaceutical and rare disease expert adopts name of global parent to reflect breadth of offer that brings a rare and special perspective to the market

Terebellum adopts the name of its global parent, AscellaHealth.